Diffuse large B-cell lymphoma response rituximab-PMitCEBO regimen is not predicted by FcγRIIa158 polymorphism
Cristina Bagacean
(1, 2, 3, 4)
,
Naelle Lombion
(5)
,
Adrian Tempescul
(3, 5, 1)
,
Jean-Christophe Ianotto
(5)
,
Christian Berthou
(3, 5, 1)
,
Mihnea Zdrenghea
(2, 4)
,
Victor Cristea
(2)
1
LabEX IGO Immunothérapie Grand Ouest
2 UMF - Iuliu Haţieganu University of Medicine and Pharmacy of Cluj-Napoca = Universitatea de Medicină şi Farmacie Iuliu Haţieganu din Cluj-Napoca
3 EA2216 - Immunologie et Pathologie
4 “Prof. Dr. Ion Chiricuta” Oncologic Insitute Cluj-Napoca
5 Department of Clinical Hematology, Institute of Cancerology and Hematology
2 UMF - Iuliu Haţieganu University of Medicine and Pharmacy of Cluj-Napoca = Universitatea de Medicină şi Farmacie Iuliu Haţieganu din Cluj-Napoca
3 EA2216 - Immunologie et Pathologie
4 “Prof. Dr. Ion Chiricuta” Oncologic Insitute Cluj-Napoca
5 Department of Clinical Hematology, Institute of Cancerology and Hematology
Adrian Tempescul
- Function : Author
- PersonId : 908115
Jean-Christophe Ianotto
- Function : Author
- PersonId : 871447
Christian Berthou
- Function : Author
- PersonId : 901901